GSK Reaches ‘First Base’ In Hep B Functional Cure But Has More To Prove
9% Disease Free After Phase II Study
GSK is the first to raise the functional cure rate with its antisense drug, Phase II data suggest, but the company is looking for ways to boost responses across hepatitis B patients in its Phase III study.
You may also be interested in...
The DREAMM-3 study was meant to be a confirmatory study for Blenrep, and its failure raises concerns over its use in earlier lines of therapy and the possibility that it could be removed from the market.
Having established Enhertu as their first antibody-drug conjugate blockbuster, AstraZeneca and Daiichi Sankyo are looking to challenge Gilead in the TROP2-targeting field as well.
Early data in Gaucher disease suggest Avrobio’s hematopoietic stem cell gene therapy could help patients who do not response to enzyme replacement therapy.